# Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients

> **NCT00891475** · PHASE1,PHASE2 · COMPLETED · sponsor: **Kidney Cancer Research Bureau** · enrollment: 114 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **PROCEDURE:** Radiofrequency ablation; Interferon-alpha
- **PROCEDURE:** Radiofrequency ablation; Sunitinib maleate
- **DRUG:** Sunitinib maleate

## Key facts

- **NCT ID:** NCT00891475
- **Lead sponsor:** Kidney Cancer Research Bureau
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2010-01
- **Final completion:** 2011-01
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2014-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00891475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00891475, "Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00891475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*